Patents by Inventor Balamurali K. Ambati
Balamurali K. Ambati has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230256012Abstract: An ophthalmic composition or dosage form can include a therapeutically effective amount of a copper-containing agent that is sufficient to increase corneal lysyl oxidase activity in an eye of a subject in an amount sufficient to treat myopic progression and a pharmaceutically acceptable carrier. The composition or dosage form can be used to treat or prevent progression of myopia by administering a therapeutically effective amount of the composition to an eye of a subject during a treatment period.Type: ApplicationFiled: December 13, 2022Publication date: August 17, 2023Applicant: University of Utah Research FoundationInventors: Randon Michael Burr, Balamurali K. Ambati, Sarah A. Molokhia
-
Publication number: 20220401580Abstract: Provided are nucleotide sequences encoding polypeptides with ribonuclease III activity, wherein the nucleotide sequences have been modified to reduce their regulation by miRNAs. In some embodiments, the nucleotide sequences are at least 50% and as much as 100% identical to SEQ ID NO: 20 or SEQ ID NO: 22, and/or encode polypeptides that are at least 90% percent identical to SEQ ID NO: 23. Also provided are vectors and host cells that include the nucleotide sequences, methods for expressing the nucleotide sequences in cells, tissues, and organs, which in some embodiments can be in the eye of a subject in need thereof, methods for preventing and/or treating development of diseases or disorders and/or for restoring undesirably low DICER1 expression using the nucleotide sequences, and pharmaceutical compositions that have the presently disclosed nucleotide sequences.Type: ApplicationFiled: November 12, 2020Publication date: December 22, 2022Applicants: University of Virginia Patent Foundation, University of Utah Research FoundationInventors: Jayakrishna Ambati, Bradley David Unti Gelfand, Balamurali K. Ambati, Hironori Uehara
-
Patent number: 11524032Abstract: An ophthalmic composition or dosage form can include a therapeutically effective amount of a copper-containing agent that is sufficient to increase corneal lysyl oxidase activity in an eye of a subject in an amount sufficient to treat myopic progression and a pharmaceutically acceptable carrier. The composition or dosage form can be used to treat or prevent progression of myopia by administering a therapeutically effective amount of the composition to an eye of a subject during a treatment period.Type: GrantFiled: January 7, 2019Date of Patent: December 13, 2022Assignee: University of Utah Research FoundationInventors: Randon Michael Burr, Balamurali K. Ambati, Sarah A. Molokhia
-
Publication number: 20220288114Abstract: Opthalmic compositions are disclosed and described herein. In some embodiments, an ophthalmic composition can include as active agents a copper-containing agent and a secondary therapeutic agent in combination with a pharmaceutically acceptable carrier. The active agents can be present in amounts sufficient to treat myopic progression during a treatment period.Type: ApplicationFiled: July 13, 2020Publication date: September 15, 2022Applicant: University of Utah Research FoundationInventors: Randon Michael Burr, Balamurali K. Ambati, Sarah A. Molokhia
-
Publication number: 20220031449Abstract: Methods for a patient surgically receiving a customized IOL for a particular eye according to patient-specific measurement data are provided. The methods may include preoperative evaluation of a particular eye of a particular patient and accumulation of patient-specific measurement data by a physician and/or a hospital. The physician, designee, and/or hospital may transmit the measurement data for the patient to the customized IOL manufacturer. The IOL manufacturer may manufacture and customize the IOL. The manufacturer may deliver the customized IOL back to the surgeon, designee, and/or hospital, after which the surgeon may perform the surgery.Type: ApplicationFiled: July 31, 2019Publication date: February 3, 2022Inventor: Balamurali K. Ambati
-
Publication number: 20210322470Abstract: An ophthalmic composition or dosage form can include a therapeutically effective amount of a cross-linking agent and a pharmaceutically acceptable carrier. The composition or dosage form can be used to treat an ophthalmic condition by administering a therapeutically effective amount of the composition to an eye of a subject during a treatment period.Type: ApplicationFiled: June 28, 2021Publication date: October 21, 2021Applicant: University of Utah Research FoundationInventors: Balamurali K. Ambati, Hironori Uehara, Santosh Muddana
-
Patent number: 11065275Abstract: An ophthalmic composition or dosage form can include a therapeutically effective amount of a cross-linking agent and a pharmaceutically acceptable carrier. The composition or dosage form can be used to treat an ophthalmic condition by administering a therapeutically effective amount of the composition to an eye of a subject during a treatment period.Type: GrantFiled: December 6, 2016Date of Patent: July 20, 2021Assignee: University of Utah Research FoundationInventors: Balamurali K. Ambati, Hironori Uehara, Santosh Muddana
-
Publication number: 20210060059Abstract: An ophthalmic composition or dosage form can include a therapeutically effective amount of a copper-containing agent that is sufficient to increase corneal lysyl oxidase activity in an eye of a subject in an amount sufficient to treat myopic progression and a pharmaceutically acceptable carrier. The composition or dosage form can be used to treat or prevent progression of myopia by administering a therapeutically effective amount of the composition to an eye of a subject during a treatment period.Type: ApplicationFiled: January 7, 2019Publication date: March 4, 2021Applicant: University of Utah Research FoundationInventors: Randon Michael Burr, Balamurali K. Ambati, Sarah A. Molokhia
-
Publication number: 20210030531Abstract: Methods for a patient surgically receiving a customized IOL for a particular eye according to patient-specific measurement data are provided. The methods may include preoperative evaluation of a particular eye of a particular patient and accumulation of patient-specific measurement data by a physician and/or a hospital. The physician, designee, and/or hospital may transmit the measurement data for the patient to the customized IOL manufacturer. The IOL manufacturer may manufacture and customize the IOL. The manufacturer may deliver the customized IOL back to the surgeon, designee, and/or hospital, after which the surgeon may perform the surgery.Type: ApplicationFiled: July 31, 2019Publication date: February 4, 2021Inventor: Balamurali K. Ambati
-
Patent number: 10588855Abstract: Devices, systems, and methods for delivery of an active agent from the lens capsule to a posterior segment of the eye of a subject can include an intraocular active agent delivery device including an active agent dispersed within a biodegradable active agent matrix. The active agent includes dexamethasone and the delivery device is adapted to fit within a lens capsule or ciliary sulcus of an eye. The delivery device can be inserted into the lens capsule or ciliary sulcus of an eye during cataract surgery or for treatment of uveitis.Type: GrantFiled: December 27, 2016Date of Patent: March 17, 2020Assignee: University of Utah Research FoundationInventors: Balamurali K. Ambati, Bruce K. Gale, Srinivas Rao Chennamaneni
-
Publication number: 20190083529Abstract: An ophthalmic composition or dosage form can include a therapeutically effective amount of a cross-linking agent and a pharmaceutically acceptable carrier. The composition or dosage form can be used to treat an ophthalmic condition by administering a therapeutically effective amount of the composition to an eye of a subject during a treatment period.Type: ApplicationFiled: December 6, 2016Publication date: March 21, 2019Applicant: University of Utah Research FoundationInventors: Balamurali K. Ambati, Hironori Uehara, Santosh Muddana
-
Publication number: 20190008837Abstract: Ophthalmic formulations and compositions employing pergolide to treat an ophthalmic or ocular condition are disclosed and described.Type: ApplicationFiled: December 15, 2017Publication date: January 10, 2019Applicant: University of Utah Research FoundationInventors: Balamurali K. Ambati, Santosh Muddana, Xiaohaui Zhang
-
Publication number: 20180250311Abstract: An intraocular active agent delivery device can include an active agent homogenously combined with a biodegradable active agent matrix such that the entire delivery device is homogenous. The homogenous delivery device can have a shape and size to fit within a lens capsule or ciliary sulcus of an eye and provide a therapeutically effective amount of the active agent to the eye. The biodegradable active agent matrix can be formulated to provide sustained release of the therapeutically effective amount of the active agent during a release period. In some examples, the active agent can include dexamethasone.Type: ApplicationFiled: January 30, 2018Publication date: September 6, 2018Inventors: Balamurali K. Ambati, Bruce K. Gale, Srinivas Rao Chennamaneni
-
Patent number: 10064819Abstract: Devices, systems, and methods for delivery of an active agent into the eye of a subject can include an intraocular active agent delivery device including an active agent dispersed within a biodegradable active agent matrix. The active agent includes dexamethasone and the delivery device is adapted to fit within a lens capsule or ciliary sulcus of an eye. The delivery device can be inserted into the lens capsule or ciliary sulcus of an eye during cataract surgery or for treatment of uveitis.Type: GrantFiled: July 6, 2012Date of Patent: September 4, 2018Assignee: University of Utah Research FoundationInventors: Balamurali K. Ambati, Bruce K. Gale, Srinivas Rao Chennamaneni
-
Patent number: 9877973Abstract: An intraocular active agent delivery device can include an active agent homogenously combined with a biodegradable active agent matrix such that the entire delivery device is homogenous. The homogenous delivery device can have a shape and size to fit within a lens capsule or ciliary sulcus of an eye and provide a therapeutically effective amount of the active agent to the eye. The biodegradable active agent matrix can be formulated to provide sustained release of the therapeutically effective amount of the active agent during a release period. In some examples, the active agent can include dexamethasone.Type: GrantFiled: May 9, 2017Date of Patent: January 30, 2018Assignee: University of Utah Research FoundationInventors: Balamurali K. Ambati, Bruce K. Gale, Srinivas Rao Chennamaneni
-
Publication number: 20170304367Abstract: Methods, compositions, and systems for treating ischemia-associated and other ocular conditions using cartilage oligo matrix protein-Angiopoietin 1 (COMP-Ang1) are disclosed and described.Type: ApplicationFiled: October 29, 2015Publication date: October 26, 2017Applicant: University of Utah Research FoundationInventors: Balamurali K. Ambati, Hironori Uehara, Judd Hoon
-
Publication number: 20170239272Abstract: An intraocular active agent delivery device can include an active agent homogenously combined with a biodegradable active agent matrix such that the entire delivery device is homogenous. The homogenous delivery device can have a shape and size to fit within a lens capsule or ciliary sulcus of an eye and provide a therapeutically effective amount of the active agent to the eye. The biodegradable active agent matrix can be formulated to provide sustained release of the therapeutically effective amount of the active agent during a release period. In some examples, the active agent can include dexamethasone.Type: ApplicationFiled: May 9, 2017Publication date: August 24, 2017Inventors: Balamurali K. Ambati, Bruce K. Gale, Srinivas Rao Chennamaneni
-
Publication number: 20170218363Abstract: Methods of inhibiting lymphangiogenesis and/or angiogenesis in a subject are provided. In one aspect, for example, a method of inhibiting angiogenesis in a subject can include binding an antisense morpholino to an mRNA splicing site of VEGFR1 selected from exon13_intron13 junction, intron13_exon14 junction, or a combination thereof. In another aspect, the morpholino includes a member selected from VEGFR1_MOe13, VEGFR1_MOi13, or a combination thereof.Type: ApplicationFiled: November 29, 2016Publication date: August 3, 2017Applicant: University of Utah Research FoundationInventors: Balamurali K. AMBATI, Hironori UEHARA
-
Publication number: 20170218375Abstract: Various methods and compositions relating to vascular endothelial growth factor receptor 2 (VEGFR2) are provided. In one aspect, a method of increasing expression of the soluble form of VEGFR2 (sVEGFR2) in a subject can include binding an antisense morpholino to an exon13-intron13 splicing site of VEGFR2 mRNA such that the VEGFR2 mRNA is spliced into a sVEGFR2 isoform.Type: ApplicationFiled: January 3, 2017Publication date: August 3, 2017Applicant: University of Utah Research FoundationInventors: Balamurali K. Ambati, Hironori Uehara
-
Publication number: 20170105932Abstract: Devices, systems, and methods for delivery of an active agent from the lens capsule to a posterior segment of the eye of a subject can include an intraocular active agent delivery device including an active agent dispersed within a biodegradable active agent matrix. The active agent includes dexamethasone and the delivery device is adapted to fit within a lens capsule or ciliary sulcus of an eye. The delivery device can be inserted into the lens capsule or ciliary sulcus of an eye during cataract surgery or for treatment of uveitis.Type: ApplicationFiled: December 27, 2016Publication date: April 20, 2017Inventors: Balamurali K. Ambati, Bruce K. Gale, Srinivas Rao Chennamaneni